MarketPulse

dermatology

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Dupixent Wins Japan Approval for Rare Autoimmune Disorder, Expanding Sanofi-Regeneron Pipeline

Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.
SNYREGNclinical trialDupixent
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Sol-Gel Raises $33.1M via Oversubscribed Offering to Advance Rare Disease Pipeline

Sol-Gel Technologies prices 459,112 shares at $72 each, raising $33.1M for SGT-610 development in Gorlin syndrome treatment.
SLGLPhase 3 clinical trialequity offering
GlobeNewswire Inc.GlobeNewswire Inc.··Novartis

Novartis Showcases Dermatology Pipeline Momentum With Early-Relief Data at AAD 2026

Novartis presents 20+ abstracts at AAD 2026, highlighting rapid symptom relief with Rhapsido and long-term efficacy data for Cosentyx across multiple skin conditions.
NVSchronic spontaneous urticariaimmunology
BenzingaBenzinga··Vandana Singh

Novartis Expands Cosentyx Reach Into Pediatric Dermatology With FDA Approval

Novartis wins FDA approval for Cosentyx in pediatric hidradenitis suppurativa patients aged 12+, marking the drug's fourth pediatric indication and expanding its dermatology portfolio.
NVSFDA approvalautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arcutis to Showcase Pipeline Progress at TD Cowen Healthcare Summit

Arcutis will present pipeline progress and 2025 financial results at TD Cowen Healthcare Summit in March 2026, advancing its dermatology portfolio and patient awareness initiatives.
ARQTfinancial resultsseborrheic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Castle Biosciences, Inc.

Castle Biosciences Test Predicts JAK Inhibitor Response in Atopic Dermatitis

Castle Biosciences' AdvanceAD-Tx test predicts which atopic dermatitis patients will respond to JAK inhibitors, showing 5.5x better outcomes for identified responders versus alternative treatments.
CSTLpersonalized medicineatopic dermatitis